OpGen, Curetis, and Ares Genetics have combined their businesses to build stronger diagnostic solutions for severe infections. Read more.
Rapid and comprehensive
molecular diagnostic infectious disease panels, including detection of bacterial co-infections in COVID-19 pneumonia.
A new light on antibiotic resistance
Using the power of genomics and informatics to fight antibiotic-resistant microbes
Optimizing Genomic Testing for Antibiotic Resistance
Existing tests can take days to identify the correct treatment for a patient’s infection. That’s why caregivers often use broad-spectrum antibiotics as a first defense—but when those drugs are overused, antibiotic-resistant microbes can emerge. OpGen is developing a better way to treat infection while preventing antibiotic resistance. We harness the power of informatics and genomics to identify antimicrobial resistant (AMR) organisms quickly and accurately, with an aim to improve treatment at the patient, hospital, and network level.
Video
CEO Oliver Schacht discusses the new OpGen
In The News
COVID-19 patients at risk for bacterial pneumonia co-infection.
Publications
OpGen accurately and reliably predicts antibiotic resistance in comprehensive study